Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Novo Nordisk's collaboration with telehealth providers offers semaglutide at $499/month ... ensuring a streamlined process for prescription management and follow-up. This approach allows for ...

Novo Nordisk, the Danish company that produces the semaglutide drugs Ozempic and ... management goals,” the company said. After the process is complete, a new investor group will wield 91% ...

As a result, it is now illegal under U.S. compounding laws to make or sell compounded semaglutide drugs, except with rare exceptions. Novo Nordisk is ... days in an ongoing process.

As Novo Nordisk works through a period of transition in the U.S. GLP-1 drug market, sales from the company's star obesity medicine Wegovy came in below expectations in the first quarter of 2025.

Moreover, Novo Nordisk also claims that it is difficult to manufacture liraglutide and "even small changes in the manufacturing process of ... made a similar case for semaglutide in a petition ...

Danish pharmaceutical giant Novo Nordisk scored a ... members for making copies of semaglutide, the active ingredient in Ozempic and Wegovy. Compounding is a process where pharmacies mix ...

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight ...

The deal, announced in March and set to close in the second quarter, marks the Swiss pharma's latest bid to compete with weight loss heavyweights Novo Nordisk and Eli Lilly, after building out its ...